You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CE

Sharing Stories in R/R CLL: An Opportunity to Interact With the Nurse Experts

  • Authors: Beth Faiman, PhD, MSN, RN, APRN-BC, AOCN; Sandra Kurtin, PhDc, MS, RN, AOCN, ANP-C; Laura J. Zitella, MS, RN, ACNP-BC, AOCN
  • CE Released: 6/24/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 6/24/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for nurses and nurse practitioners.

The goal of this activity is to provide clinically valuable information about adverse events that may occur in patients treated for relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL).

Upon completion of this activity, participants will

  • Have increased knowledge regarding the
    • Adverse events associated with treatment for R/R CLL
  • Have greater competence related to
    • Educating patients and caregivers about recognizing adverse events of treatment for R/R CLL
    • Mitigating adverse events in patients being treated for R/R CLL


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Beth Faiman, PhD, MSN, RN, APRN-BC, AOCN

    Nurse Practitioner
    Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio

    Disclosures

    Disclosure: Beth Faiman, PhD, MSN, RN, APRN-BC, AOCN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Takeda Pharmaceuticals North America, Inc.
    Received grants for clinical research from: Carevive Systems, Inc.

    Dr Faiman does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Faiman does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Sandra Kurtin, PhDc, MS, RN, AOCN, ANP-C

    Hematology/Oncology Nurse Practitioner
    University of Arizona Cancer Center
    Assistant Professor of Clinical Medicine
    Adjunct Professor of Nursing
    University of Arizona
    Tucson, Arizona

    Disclosures

    Disclosure: Sandra Kurtin, PhDc, AOCN, ANP-C, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Celgene Corporation; Pharmacyclics, Inc.; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Genentech, Inc.

    Dr Kurtin does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by FDA for use in the United States.

    Dr Kurtin does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Laura J. Zitella, MS, RN, ACNP-BC, AOCN

    Lead Advanced Practice Provider/Nurse Practitioner
    Inpatient Hematology/Oncology
    Stanford Health Care
    Palo Alto, California

    Disclosures

    Disclosure: Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Array BioPharma
    Owns stock, stock options, or bonds from: Kite Pharma Inc.

    Ms Zitella does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Zitella does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Faculty

  • Maura E. Abbott, PhD, AOCNP, CPNP

    Columbia University School of Nursing
    Columbia University Medical Center
    New York, New York

    Disclosures

    Disclosure: Maura E. Abbott, PhD, AOCNP, CPNP, has disclosed no relevant financial relationships.

    Dr Abbott does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Abbott does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Carmel L. Cayanan, RN

    Columbia University Irving Medical Center
    New York, New York

    Disclosures

    Disclosure: Carmel L. Cayanan, RN, has disclosed no relevant financial relationships.

    Ms Cayanan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Cayanan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Patricia Mangan, CRNP

    University of Pennsylvania
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Patricia Mangan, CRNP, has disclosed the following relevant financial relationships:
    Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Celgene Corporation; Kite Pharma Inc.; Takeda Pharmaceuticals North America, Inc.

    Ms Mangan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Mangan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Nadeen Robinson, RN, BSN, OCN

    New York Presbyterian Hospital
    Columbia University Medical Center
    New York, New York

    Disclosures

    Disclosure: Nadeen Robinson, RN, MSN, OCN, has disclosed no relevant financial relationships.

    Ms Robinson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Robinson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC

    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Barbara Barnes Rogers, CRNP, MN, AOCN, ANP-BC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Gilead Sciences, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.
    Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Genentech, Inc.; Seattle Genetics, Inc.; Teva Pharmaceuticals USA

    Ms Rogers does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Rogers does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Christina Russomanno, MSN, RN, NP-C

    Columbia University Medical Center
    New York, New York

    Disclosures

    Disclosure: Christina Russomanno, MSN, RN, NP-C, has disclosed no relevant financial relationships.

    Ms Russomanno does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Russomanno does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Joseph Tariman, PhD, RN, ANP-BC

    De Paul University
    Northwest Oncology Hematology
    Chicago, Illinois

    Disclosures

    Disclosure: Joseph Tariman, PhD, RN, ANP-BC, has disclosed no relevant financial relationships.

    Dr Tariman does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Tariman does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Sarah Williams, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Sarah Williams, PhD, has disclosed no relevant financial relationships.

CE Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Nurses

  • Awarded 0.75 contact hour(s) of continuing nursing education for RNs and APNs; 0.75 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CE

Sharing Stories in R/R CLL: An Opportunity to Interact With the Nurse Experts

Authors: Beth Faiman, PhD, MSN, RN, APRN-BC, AOCN; Sandra Kurtin, PhDc, MS, RN, AOCN, ANP-C; Laura J. Zitella, MS, RN, ACNP-BC, AOCNFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CE Released: 6/24/2018

Valid for credit through: 6/24/2019

processing....

Educational Impact Challenge

Assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print